Litigation Details for Puma Biotechnology, Inc. v. AstraZeneca Pharmaceuticals LP (D. Del. 2021)
✉ Email this page to a colleague
Puma Biotechnology, Inc. v. AstraZeneca Pharmaceuticals LP (D. Del. 2021)
Docket | ⤷ Try a Trial | Date Filed | 2021-09-22 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:1 Patent Infringement | Assigned To | Colm Felix Connolly |
Jury Demand | Plaintiff | Referred To | |
Parties | ASTRAZENECA PLC | ||
Patents | 8,946,235; 9,732,058 | ||
Attorneys | Kaveh V. Saba | ||
Firms | Morris, Nichols, Arsht & Tunnell | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Puma Biotechnology, Inc. v. AstraZeneca Pharmaceuticals LP
Details for Puma Biotechnology, Inc. v. AstraZeneca Pharmaceuticals LP (D. Del. 2021)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2021-11-05 | 8 | Counterclaim AND Answer to Complaint | . RESPONSE: Defendants admit that U.S. Patent Nos. 8,946,235 and 9,732,058 are listed in the FDA Orange…. RESPONSE: Defendants admit that U.S. Patent Nos. 8,946,235 and 9,732,058 are listed in the FDA Orange…U.S. Patent No. 10,603,314 (the “’314 Patent”) and U.S. Patent No. 10,596,162 (the “’162 Patent”) (collectively…United States Patent Nos. 10,603,314 (“the ’314 patent”) and 10,596,162 (“the ’162 patent”) (collectively…causes of action for patent infringement of U.S. Patent Nos. 10,603,314 (“the ’314 Patent”) and 10,596,162 | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |